Surviving the Rookie Virus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2): The Immunopathology of a SARS-CoV2 Infection

Sheng Feng Tsai1,2, Kang-Yun Lu2,3, Hong-Meng Chuang4, and Ching-Ann Liu2,5,6

Abstract
Until July 29th, the number of confirmed coronavirus (COVID-19) cases worldwide has risen to over 16 million, within which 655,300 deaths. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) emerges as the 11th global pandemic disease, showing the highest infectivity and lowest infection fatality rate. In this review, we compare the immunopathology among SARS-CoV, Middle East respiratory syndrome coronavirus, and SARS-CoV2. SARS-CoV2 is similar to SARS-CoV; it can cause lymphocytopenia and a rising granulocyte count. Here we point out the human body and concentrated society make for an excellent incubator for virus evolution. Most research energies put into developing the SARS-CoV2 vaccine are trying to block virus infection. Sixty-five percent of severe patients die with multiple organ failure, inflammation, and cytokine storm, which indicates that the patient’s immune system maintains functionality. Finding a way to trigger the specific T cell subset and plasmablast in our body is the best shot to get away with SARS-CoV2.

Keywords
SARS-CoV2, immunopathology, vaccine

Introduction
Throughout the course of history, a pandemic devastates the entire human population while simultaneously propels the human immune system evolution forward. At the same time, pathogens continue to evolve as well. At the turn of the decade, severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) emerges as the 11th global pandemic disease; its first case reported with pneumonia in Wuhan, China1,2. As of July 29, 2020, the report indicates that there are 16,540,137 SARS-CoV2 patients, 655,300 death cases, and an infection fatality rate (IFR) of 3.9% worldwide. However, this pandemic did not stem from the first coronavirus outbreak. In fact, there are seven coronaviruses found existing, of which four—HKU1, NL63, OC43 and 229E—cause mild symptoms3. SARS-CoV, more commonly known as SARS, had its first outbreak in 2002 in China, then spreading to 26 countries, leading to 8,000 confirmed cases and 774 reported deaths, resulting in an IFR of 9.3%. With good quarantine control, cases remained stagnant from mid-2003 onward. Ten years later in 2012, Middle East respiratory syndrome coronavirus (MERS-CoV), known more commonly as MERS, reported its first case in Saudi Arabia. MERS resulted in 2,494 infected cases, 858 deaths, and an IFR of 34.3%. Due to its high mortality rate and the world’s previous experience with SARS, MERS never escalated into a pandemic. It wouldn’t be for another 10 years

1 Department of Life Sciences, Agricultural Biotechnology Center, National Chung Hsing University, Taichung
2 Bioinnovation Center, Buddhist Tzu Chi Medical Foundation, Hualien
3 Graduate Institute of Basic Medical Science, China Medical University, Taichung
4 Laboratory of Translational Medicine Office, Development Center for Biotechnology, Taipei
5 Department of Medical Research, Hualien Tzu Chi Hospital, Hualien
6 Department of Neuroscience Center, Hualien Tzu Chi Hospital, Hualien

Submitted: September 25, 2020. Revised: December 16, 2020. Accepted: January 20, 2021.

Corresponding Author:
Ching-Ann Liu, Bioinnovation Center, Buddhist Tzu Chi Medical Foundation, Hualien 970.
Email: sagianne@gmail.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
until SARS-CoV2 emerges as a low mortality, fast spreading
disease, rapidly declaring itself as a pandemic.

Additional research from China indicates SARS-CoV2 as
a human immune system breaker, causing lymph node and
spleen necrosis, leading to lymphocytopenia. Like
SARS-CoV2, HIV and DENGUE also lead to lymphocytopenia.
Unlike SARS-CoV2, however, HIV and DENGUE virus transmission pathways are different. In addition, HIV
and DENGUE have existed in human society for over two
centuries. With our healthcare and medical research technol-
ygies improvements, these two viruses have become chronic
diseases. If we control them well, they won’t become a life-
threatening issue. Coronavirus, however, is a rookie virus;
their transspecies just only 30 years. In this article, we will
discuss coronavirus, including not only SARS-CoV2 but
SARS-CoV and MERS-CoV, the immune system response,
and how to improve the human survival rate from a SARS-
CoV2 infection.

Severe Acute Respiratory Syndrome Coronavirus 2

SARS-CoV2 broke out in Wuhan in 2019 with pneumonia
symptoms related to acute inflammation and immune system
activation. After gene sequencing SARS-CoV2, results show
that SARS-CoV2 uses the SARS-CoV receptor ACE2 to
to enter the host cell, and the host cell’s serine protease
TMPRSS2 is helping spike S protein priming. According to research from Wuhan, China, they collected
522 patients with confirmed SARS-CoV2 infection and
compared them with 40 healthy patients. The adaptive
immune system cell, CD8+ T cell and CD4+ T cell, count
number is lower than 300 and 400 cell/ml, respectively.

Further, they compared mild disease and severe diseased
(SD) patients. SD patient showed the lowest CD8+ and
CD4+ T cell counts. Another research from Hubei,
China, showed similar results. After SARS-CoV2 infection,
infected patients’ T cell counts decreased. In fact, not only
did the T cell counts decreased but also the NK cells. For
those who survived SAR-CoV2, their T cell and NK cell number restored7.

In general, Alveolar macrophage destroys the patho-
gen, bacteria, virus, dust via phagocytosis, digests them
into segments, and presents them to the adaptive immune
cell. Macrophage as an antigen presenting cell, APC, connects innate immune response to adaptive immune
response. Because of lymphocytopenia, Dr Cheng, from
Chongqing, studied six patient autopsies to examine the
secondary lymphoid organ spleen and lymph node. They
found that interstitial macrophage expresses the ACE2
receptor and that some of these macrophages also contain
the SARS-CoV2 nucleocapsid protein. The severely dam-
aged tissue, splenic nodule atrophy, and TUNEL assay
show a lot of apoptosis in the lymph node and spleen4,
which means SARS-CoV2 infection can cause lymphocyto-
penia by macrophage-induced cytokine storm in lymph
node and spleen.

Severe Acute Respiratory Syndrome Coronavirus

Before the emergence of SARS-CoV2, there were seven
other coronaviruses present. HCoV-NL63, HCoV-299E,
and HCoV-OC43 were baby viruses causing mild
respiratory tract infections. HCoV-HKU1 was first
detected in a child nasal sample in 1995, but the first
patient was discovered in 2004 along with pneumonia.
HKU1 was the first coronavirus known to cause pneu-
monia. And in 2002, SARS-CoV had its outbreak in
Guangdong, China11.

SARS-CoV was the first coronavirus epidemic in human
history. As the outbreak occurred only in Guangdong in the
beginning, most known study of SARS relied heavily on
reports made in China. In a study with 138 SARS patients,
100% have fever, and 69.9% showed lymphopenia. According to their six autopsy cases, they reported a lot of monocyte, lymphocyte, and plasma cell infiltrating in the alveolar necrosis lesion. Lymph node and lymphoid organ showed massive necrosis as well. Hyperactive immune cell including monocyte, lymphocyte, and plasma cell infiltrated the heart, liver, kidney, and many other organs. The SARS outbreak in Toronto noted that of the 144 patients that were infected with SARS-CoV, 77% were exposed to SARS in the hospital. Their report is similar to China’s study. Neutrophil and lymphocyte counts were below the average (3,600/7,500, 900/4,000). In 2006, Jiang Gu reported CD8+, CD4+, plasma cell, and APC were significantly decreased in SARS spleen red pulp area. Each lymphocyte subset and NK cell were decreased 65%-95%. The direct injury is caused by virus infected, but most indirect injury in multiple organ results from hyper-activate immune response.

**Middle East Respiratory Syndrome Coronavirus**

In 2012, a SARS-CoV-like case was reported from a hospital in Jeddah, Saudi Arabia. Dr Fouchier conducted a test
capable of detecting all known coronaviruses up to date. The results indicated that the virus was a novel coronavirus that had never been seen before. The novel coronavirus was termed the Middle East respiratory syndrome coronavirus, MERS-CoV. MERS-CoV shows a lower level human-to-human transmission. Until 2015, there were 1,633 confirmed infected MERS cases. According to the report from WHO, 587 deaths were due to MERS-CoV. In the beginning, MERS was called the novel human betacoronavirus EMC (HCoV-EMC). Forty-seven MERS patients showed 14% leukopenia and 37% lymphopenia. One case report showed WBC count is on normal level, but with high percentage of neutrophils (92.5%) and lower percentage of lymphocyte (4.3%).

Contrary to SARS-CoV, MERS-CoV’s spike protein binds to human DPP4 and not ACE2. Although MERS’ spike protein ligand is different to SARS, it still stimulates tons of cytokine and chemokine to secrete from the immune cell. In severe MERS patients, there was high level IL-6, IL-8, IFNα, and CCL5 in serum.

How to Get Away with SARS-CoV2
So far, the development of SARS-CoV2 vaccine base on synthetic spike protein. One problem in the vaccine development process is spike protein modification in our cell is the same structure compared to synthetic spike protein. Viral surface protein glycosylation plays vital role in infection. Some glycosylation can protect virus from immune surveillance. Most of SARS-CoV2 vaccine study used synthetic plasmid transfect mammalian cell line to check their vaccine work or not. In reality, after SARS-CoV2 infection, virus infection stage from latency to lytic, hijack the host cell to translate viral protein to package the particle. At that time, mammalian cell might help viral coating protein do the post translation modification. That’s why some study showed the S protein of SARS-CoV2 has 22 N-linked glycosylation site. They trying to find out which site is critical to virus entry as a new target to developed vaccine or antibody. But the question is our developing vaccine and antibody can completely block the virus, and we won’t never face it again. After 20 years coronavirus evolution, the IFR from 9.5% to 5.6%. Until June, there are some news report, the second wave outbreak infection in Beijing, South Korea, and the United States.

Social distancing and strategic quarantine may be effective in the beginning. When faced with the a life-threatening unknown, our first response is “do not touch anything,” allowing ourselves the time to analyze in order to eliminate them by using structural analysis and neutralizing antibody development. However, once we realize there is no way to stop the spreading, we resort to hostile co-living, desperately trying not to be murdered like the influenza and HIV. Currently, SARS-CoV2 patients can be divided into mild, medium, and severe symptoms. Most mild and medium patients can be cured by themselves after a fever.

Sixty-five percent of severe patients die with multiple organ failure, inflammation, and cytokine storm, which means that the patient’s immune system did work. But the host immune system cannot clean the rapidly replicated virus. With tons of inflammation cytokine secreted, they accumulate in infectious organ, leading to multiple organ failure. In addition, the human body and society is a good incubator for the virus evolution. The virus mutation can cause the vaccine development bubble explode. The research from the United States found SARS-CoV2 spike protein mutate on D614G site and cause three times higher infectious rate.

The true question lies in how can we manually control our immune system response to SARS-CoV2. Rapidly wiping out the SARS-CoV2 infection is the only way to win that war. More and more research are starting to compare the difference between healthy and acute respiratory distress syndrome patients with SARS-CoV2. Data show that severe SARS-CoV2 patients were depleted of γδ T cells, dendritic cells, and NK cells. But more interestingly, plasmablasts as an antibody secreting cell increased, which means severe cases might also cause a humoral immune response. CD56dim NK cell is considered as antiviral cell, CD56bright NK cell which produce INF-γ were depleted. On the other hand, each T cell subset all expression exhausted marker. MHC class II has a vital role in expression pathogen to cell surface. They found MHC class II downregulate expression in severed patient. HLA-DR expressions on T cell and B cell are reliable markers in the immune system response with acute infection not only in coronavirus but also in Ebola. In one case report, a women who was detected SARS-CoV2 by real-time polymerase chain reaction at day 4, but undetectable at day 7. All the symptoms resolved completely at day 13. HLA-DR expression on CD8+ T cell and CD4+ T cell increased from day 7 (3.57%, 0.55%) to day 9 (11.8%, 3.33%). HLA-DR+ CD8+T cell produces an amount of granzyme A, B, and peforin. HLA-DR+ expression on lymphocyte means the host immune cell specific subtype which can recognize the virus particle was activated. In 19 SARS-CoV2 patient study, the moderate patient showed high IFNG, CCL5, PRF1, but severed patient showed lower levels of CCL5 and INFG. Its seems CCR5 might be a good therapeutic target.

Combining all these evidences together, SARS-CoV2 can target our immune system and interfere with the intelligence system of human immunity. Developing CoV2 vaccine might slow them down, but cannot aid in the people who are already infected. There are two strategies to saving life, one is inhibiting the amount of proinflammatory cytokine secretion and the other is letting the immune response find the way out. It takes time, but it will work. The alternative is to find a way to trigger the specific T cell subset and plasmablast in our body, and eliminate the viral particle to lower our immune tolerance.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This review was funded by Buddhist Tzu Chi Bioinnovation Center, Tzu Chi Foundation (MF00A1308SS04), and the Ministry of Science and Technology (MOST 109-2320-B-303-006).

ORCID iD

Kang-Yun Lu https://orcid.org/0000-0002-0028-5566
Hong-Meng Chuang https://orcid.org/0000-0003-1978-3618
Ching-Ann Liu https://orcid.org/0000-0002-0392-7069

References

1. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L, Chen HD, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273.
2. Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, Hu Y, Tao Z-W, Tian J-H, Pei Y-Y, Yuan ML, et al. A novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes. medRxiv. 2020;2003.02.27.20045427.
3. Corman VM, Muth D, Niemeyer D, Drosten C. Hosts and sources of endemic human coronaviruses. Adv Virus Res. 2018;100:163–188.
4. Chen Y, Feng Z, Diao B, Wang R, Wang G, Wang C, Tan Y, Liu L, Wang C, Liu Y, Liu Y, et al. The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes. medRxiv. 2020;2003.02.27.20045427.
5. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Hettler W, Nitsche A, Müller MA, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8.
6. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, Chen L, Liu Y, Wang G, Yuan Z, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020;11:827.
7. Zheng M, Gao Y, Song G, Liu S, Sun D, Xu Y, Tian Z. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533–535.
8. Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, Li T, Chen Q. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):1–5.
9. Sungnak W, Huang N, Bécavin C, Berg M, Queen R, Litvinukova M, Talavera-López C, Maatz H, Reichart D, Sampaziotis F, Worlock KB, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26(5):681–687.
10. Chua RL, Lukassen S, Trump S, Hennig BP, Wendisch D, Pott F, Deb Nath O, Thürmann L, Kurth F, Völker MT, Kazmierski J, et al. COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis. Nat Biotechnol. 2020;38(8):970–979.
11. Zhao Z, Zhang F, Xu M, Huang K, Zhong W, Cai W, Yin Z, Huang S, Deng Z, Wei M, Xiong J, et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol. 2003;52(8):715–720.
12. Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, Ahuja A, Yung MY, Leung C, To K, Lui SF, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348(20):1986–1994.
13. Ding Y, Wang H, Shen H, Li Z, Geng J, Han H, Cai J, Li X, Kang W, Weng D. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J Pathol. 2003;200(3):282–289.
14. Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, Walmsley SL, Mazzulli T, Avendano M, Derkach P, Ephimios IE, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003;289(21):2801–2809.
15. Zhan J, Deng R, Tang J, Zhang B, Tang Y, Wang JK, Li F, Anderson VM, McNutt MA, Gu J. The spleen as a target in severe acute respiratory syndrome. FASEB J. 2006;20(13):2321–2328.
16. Guo Y, Korteweg C, McNutt MA, Gu J. Pathogenetic mechanisms of severe acute respiratory syndrome. Virus Res. 2008;133(1):4–12.
17. van Boeheimen S, Bestebroer TM, Verhagen JH, Osterhaus AD, Pas SD, Herfst S, Fouchier RA. A family-wide RT-PCR assay for detection of paramyxoviruses and application to a large-scale surveillance study. PloS One. 2012;7(4):e34961.
18. Faridi U. Middle East respiratory syndrome coronavirus (MERS-CoV): impact on Saudi Arabia, 2015. Saudi J Biol Sci. 2018;25(7):1402–1405.
19. Assiri A, Al-Tawfiq JA, Al-Rabeeaah AA, Al-Rabiaah FA, Al-Hajjar S, Al-Barrak A, Flemban H, Al-Nasirr WN, Balkhy HH, Al-Hakeem RF, Mahkdoom HQ, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013;13(9):752–761.
20. Zaki AM, Van Boeheimen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(20):1814–1820.
21. Raj VS, Mou H, Smits SL, Dekkers DH, Müller MA, Dijkman R, Muth D, Demmers JA, Zaki A, Fouchier RA, Thiell V, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495(7440):251–254.
22. Min C-K, Cheon S, Ha N-Y, Sohn KM, Kim Y, Aigerim A, Shin HM, Choi J-Y, Inn K-S, Kim J-H, Moon JY, et al. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. Sci Rep. 2016;6(1):1–12.
23. Watanabe Y, Allen JD, Wrapp D, McElhaney JS, Crispin M. Site-specific glycan analysis of the SARS-CoV-2 spike. Science. 2020;369(6501):330–333.
24. Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 Spike glycoprotein. Cell. 2020;181(2):281–292.e6.

25. Pires-Afonso Y, Niclou SP, Michelucci A. Revealing and harnessing tumour-associated microglia/macrophage heterogeneity in glioblastoma. Int J Mol Sci. 2020;21(3):689.

26. Xu S, Li Y. Beware of the second wave of COVID-19. Lancet. 2020;395(10233):1321–1322.

27. Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID-19 and multi-organ response. Curr Probl Cardiol. 2020;45(8):100618.

28. Zhang L, Jackson CB, Mou H, Ojha A, Rangarajan ES, Izard T, Farzan M, Choe H. The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. bioRxiv. 2020:2020.06.12.148726.

29. Wilk AJ, Rustagi A, Zhao NQ, Roque J, Martínez-Colón GJ, McKechnie JL, Ivison GT, Ranganath T, Vergara R, Hollis T, Simpson LJ, et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat Med. 2020;26(7):1070–1076.

30. Ruibal P, Oestereich L, Lüdtke A, Becker-Ziaja B, Wozniak DM, Kerber R, Korva M, Cabeza-Cabrero M, Bore JA, Koundouno FR, Duraffour S, et al. Unique human immune signature of Ebola virus disease in Guinea. Nature. 2016;533(7601):100–104.

31. Thevarajan I, Nguyen TH, Koutsakos M, Druce J, Caly L, van de Sandt CE, Jia X, Nicholson S, Catton M, Cowie B, Tong SYC, et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med. 2020;26(4):453–455.